Atherosclerosis is a chronic vascular disease and the most common pathological change of cardiovascular disease. Its pathogenesis is closely related to inflammation, oxidative stress, lipid accumulation, and calcinosis. Tetramethylpyrazine plays an anti-atherosclerotic role by regulating lipid metabolism, inhibiting foam cell formation, alleviating inflammation, inhibiting vascular calcification and abnormal platelet activation, and has a cardiovascular protective effect. Therefore, this paper summarized the research progress of the anti-atherosclerosis effect and mechanism of tetramethylpyrazine.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: